Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.

Wrinkles
Galderma is looking to compete in the market dominated by Botox • Source: Shutterstock

It appears that Galderma S.A.’s long-acting wrinkle-reducing injectable relabotulinumtoxinA will be well positioned to compete in the highly competitive neurotoxin category – if it gets approved by the US Food and Drug Administration.

Key Takeaways

  • Galderma announced topline results from two Phase IIIb studies, investigating relabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines.

The Swiss dermatology specialist announced topline results from two Phase IIIb studies on 30 November, investigating relabotulinumtoxinA for the treatment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D